Recap: Albireo Pharma Q1 Earnings

Shares of Albireo Pharma ALBO were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 60.43% year over year to ($2.23), which may not compared to the estimate of ($1.36).

Revenue of $1,549,000 higher by 171.75% from the same period last year, which beat the estimate of $1,030,000.

Guidance

Albireo Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 07, 2020

Webcast URL: http://public.viavid.com/player/index.php?id=138368

Recent Stock Performance

Company's 52-week high was at $38.69

52-week low: $11.26

Price action over last quarter: Up 3.09%

Company Profile

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.